Dynamic study of immunoregulatory factors and tumor markers in patients with advanced gastric cancer before and after chemotherapy

中国综合临床 Pub Date : 2019-09-01 DOI:10.3760/CMA.J.ISSN.1008-6315.2019.05.004

Shi-Yu Jiang

{"title":"Dynamic study of immunoregulatory factors and tumor markers in patients with advanced gastric cancer before and after chemotherapy","authors":"Shi-Yu Jiang","doi":"10.3760/CMA.J.ISSN.1008-6315.2019.05.004","DOIUrl":null,"url":null,"abstract":"Objective \nTo analyze the dynamic changes of immunoregulatory factors and tumor markers before and after chemotherapy in patients with advanced gastric cancer. \n \n \nMethods \nFrom October 2015 to February 2018, 58 patients with chemotherapy AGC in our hospital were selected as gastric cancer group.According to the efficacy of chemotherapy they were divided into effective group, stable group and ineffective group.Meanwhile, 30 healthy persons were selected as normal group.The immunoglobulins (IgA, IgG, IgM), T lymphocyte subsets (CD3+ , CD4+ , CD8+ , CD4+ /CD8+ ) and related tumor markers (CEA, CA199, CA242) were compared before and after chemotherapy. \n \n \nResults \nThe levels of IgA((2.11±0.89) g/L), IgM((10.65±4.61) g/L), IgG((1.25±0.45) g/L), CD8+ ((28.12±3.56)%), CEA((40.33±16.24) μg/L), CA199((76.34±21.56) kU/L) and CA242((29.34±9.57)k U/L) in the gastric cancer group were significantly higher than those in the normal group IgA((0.93±0.36) g/L), IgM((6.46±3.59) g/L), IgG((0.65±0.32) g/L), CD8+ ((25.02±4.78)%), CEA((1.81±0.55) μg/L), CA199((7.51±2.67) kU/L), CA242((3.35±1.21) kU/L)(t=6.958, 3.600, 6.495, 3.435, 12.952, 17.370, 14.773, P<0.05), while CD3+ ((64.12±5.12)%), CD4+ ((34.12±4.10)%), CD4+ /CD8+ (1.09±0.28) were lower than the normal group (CD3+ (71.23±7.14)%, CD4+ (39.78±5.20)%, CD4+ /CD8+ (1.47±0.40))(t=5.376, 5.592, 5.192, P<0.05). The total effective rate of AGC patients in gastric cancer group was 79.31 % (46/58), and the ineffective rate was 20.69 % (12/58). IgA, IgG, IgM, and CD8+ in the effective group were significantly lower than those before chemotherapy (t=3.925, 3.745, 4.036, 2.661, P<0.05), while CD3+ , CD4+ , CD4+ /CD8+ were significantly higher than before chemotherapy (t=3.520, 3.077, 3.218, P<0.05). The subcellular level of protein and T lymphocytes was significantly better than that of stable group and ineffective group (P<0.05). The levels of tumor markers CEA, CA199 and CA242 in the effective group and stable group were significantly lower than those before chemotherapy (P<0.05), and significantly lower than the ineffective group (P<0.05). \n \n \nConclusion \nThe levels of immunoglobulins, T lymphocyte subsets and tumor markers in patients with AGC have significant changes after chemotherapy, and their levels can guide the efficacy of chemotherapy. \n \n \nKey words: \nAdvanced gastric cancer; Chemotherapy; Immunoglobulin; T lymphocyte subsets; Tumor markers","PeriodicalId":10365,"journal":{"name":"中国综合临床","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国综合临床","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1008-6315.2019.05.004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To analyze the dynamic changes of immunoregulatory factors and tumor markers before and after chemotherapy in patients with advanced gastric cancer. Methods From October 2015 to February 2018, 58 patients with chemotherapy AGC in our hospital were selected as gastric cancer group.According to the efficacy of chemotherapy they were divided into effective group, stable group and ineffective group.Meanwhile, 30 healthy persons were selected as normal group.The immunoglobulins (IgA, IgG, IgM), T lymphocyte subsets (CD3+ , CD4+ , CD8+ , CD4+ /CD8+ ) and related tumor markers (CEA, CA199, CA242) were compared before and after chemotherapy. Results The levels of IgA((2.11±0.89) g/L), IgM((10.65±4.61) g/L), IgG((1.25±0.45) g/L), CD8+ ((28.12±3.56)%), CEA((40.33±16.24) μg/L), CA199((76.34±21.56) kU/L) and CA242((29.34±9.57)k U/L) in the gastric cancer group were significantly higher than those in the normal group IgA((0.93±0.36) g/L), IgM((6.46±3.59) g/L), IgG((0.65±0.32) g/L), CD8+ ((25.02±4.78)%), CEA((1.81±0.55) μg/L), CA199((7.51±2.67) kU/L), CA242((3.35±1.21) kU/L)(t=6.958, 3.600, 6.495, 3.435, 12.952, 17.370, 14.773, P<0.05), while CD3+ ((64.12±5.12)%), CD4+ ((34.12±4.10)%), CD4+ /CD8+ (1.09±0.28) were lower than the normal group (CD3+ (71.23±7.14)%, CD4+ (39.78±5.20)%, CD4+ /CD8+ (1.47±0.40))(t=5.376, 5.592, 5.192, P<0.05). The total effective rate of AGC patients in gastric cancer group was 79.31 % (46/58), and the ineffective rate was 20.69 % (12/58). IgA, IgG, IgM, and CD8+ in the effective group were significantly lower than those before chemotherapy (t=3.925, 3.745, 4.036, 2.661, P<0.05), while CD3+ , CD4+ , CD4+ /CD8+ were significantly higher than before chemotherapy (t=3.520, 3.077, 3.218, P<0.05). The subcellular level of protein and T lymphocytes was significantly better than that of stable group and ineffective group (P<0.05). The levels of tumor markers CEA, CA199 and CA242 in the effective group and stable group were significantly lower than those before chemotherapy (P<0.05), and significantly lower than the ineffective group (P<0.05). Conclusion The levels of immunoglobulins, T lymphocyte subsets and tumor markers in patients with AGC have significant changes after chemotherapy, and their levels can guide the efficacy of chemotherapy. Key words: Advanced gastric cancer; Chemotherapy; Immunoglobulin; T lymphocyte subsets; Tumor markers

查看原文本刊更多论文

晚期癌症患者化疗前后免疫调节因子和肿瘤标志物的动态研究

目的分析晚期癌症患者化疗前后免疫调节因子和肿瘤标志物的动态变化。方法选择我院2015年10月至2018年2月收治的58例化疗AGC患者为癌症组。根据化疗效果将其分为有效组、稳定组和无效组。同时选择30名健康人作为正常对照组。比较化疗前后免疫球蛋白（IgA、IgG、IgM）、T淋巴细胞亚群（CD3+、CD4+、CD8+、CD4+/CD8+）和相关肿瘤标志物（CEA、CA199、CA242）的变化。结果癌症组IgA（2.11±0.89）g/L、IgM（10.65±4.61）g/L、IgG（1.25±0.45）g/L、CD8+（28.12±3.56）%、CEA（40.33±16.24）μg/L、CA199（76.34±21.56）kU/L）和CA242（29.34±9.57）kU/L）水平显著高于正常组IgA水平（0.93±0.36）g/L）、IgM水平（6.46±3.59）g/L）、IgG（（0.65±0.32）g/L）、CD8+（25.02±4.78）%、CEA（1.81±0.55）μg/L），CA199（（7.51±2.67）kU/L）、CA242（（3.35±1.21）kU/L）（t=6.958、3.600、6.495、3.435、12.952、17.370、14.773，P<0.05），CD3+（（64.12±5.12）%）、CD4+（34.12±4.10）%、CD4+/CD8+（1.09±0.28）低于正常组（CD3+（71.23±7.14）%、，CD4+/CD8+（1.47±0.40））（t分别为5.376、5.592、5.192，P＜0.05）。癌症组AGC总有效率为79.31%（46/58），无效率为20.69%（12/58）。有效组IgA、IgG、IgM和CD8+显著低于化疗前（t=3.925、3.745、4.036、2.661，P<0.05），CD3+、CD4+、，CD4+/CD8+显著高于化疗前（t=3.520，3.077，3.218，P<0.05），蛋白和t淋巴细胞亚细胞水平显著高于稳定组和无效组（P<0.05），肿瘤标志物CEA、CA199和CA242水平显著低于化疗前（P<0.05），结论AGC患者化疗后免疫球蛋白、T淋巴细胞亚群和肿瘤标志物水平有显著变化，其水平可指导化疗疗效。关键词：晚期癌症；化疗；免疫球蛋白；T淋巴细胞亚群；肿瘤标志物

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中国综合临床

CiteScore

0.10

自引率

0.00%

发文量

16855

期刊介绍： Clinical Medicine of China is an academic journal organized by the Chinese Medical Association (CMA), which mainly publishes original research papers, reviews and commentaries in the field. Clinical Medicine of China is a source journal of Peking University (2000 and 2004 editions), a core journal of Chinese science and technology, an academic journal of RCCSE China Core (Extended Edition), and has been published in Chemical Abstracts of the United States (CA), Abstracts Journal of Russia (AJ), Chinese Core Journals (Selection) Database, Chinese Science and Technology Materials Directory, Wanfang Database, China Academic Journal Database, JST Japan Science and Technology Agency Database (Japanese) (2018) and other databases.